QED Therapeutics is currently looking to enroll children in PROPEL, a prospective clinical assessment study in children with achondroplasia. The study aims to learn more about the overall health, growth, and possible medical complications in children with achondroplasia.
200 boys and girls will participate in the study at locations worldwide. No medication will be administered; however, children successfully enrolled in PROPEL for 6 months or more may be eligible for subsequent treatment trials sponsored by QED Therapeutics.
- Be 2.5 to 10 years of age at study entry
- Have a diagnosis of achondroplasia
- Receive agreement from parents or caregivers to have their children participate and follow all study visit schedules and procedures
- Other study requirements will be reviewed in detail by the study staff
Participation in the PROPEL Study is voluntary.
To participate in or learn more about PROPEL or PROPEL 2, please contact us at: [email protected] or visit ClinicalTrials.gov.
PROPEL 2 is currently enrolling, and is an open-label, dose-escalation and dose-expansion study of infigratinib,* an FGFR1-3-selective tyrosine kinase inhibitor, in children with achondroplasia.
FGFR=fibroblast growth factor receptor.